Table 2.

Clinical characteristics of patients before and after inverse probability of treatment weighting (IPTW) in localized UTUC

Variables	Study population before IPTW (n = 492)			After IPTW match
	Non-ESA (N = 249)	ESA (N = 243)	Standardized difference	Non-ESA (N = 495.6)	ESA (N = 488.2)	Standardized difference
Follow up (mean ± SD)	69.44 ± 43.06	74.39 ± 44.72	0.113	70.20 ± 42.90	73.23 ± 44.41	0.069
Age (mean ± SD)	69.16 ± 10.58	66.11 ± 10.63	0.287	67.53 ± 10.87	67.49 ± 10.39	0.004
CCI scores (mean ± SD)	7.20 ± 3.65	7.99 ± 3.38	0.224	7.66 ± 3.75	7.70 ± 3.20	0.011
Gender-Male (%)	127.0 (51.0)	79.0 (32.5)	0.382	204.2 (41.2)	201.8 (41.3)	0.003
T stage (%)			0.138			0.017
1	121.0 (48.6)	126.0 (51.9)		249.7 (50.4)	242.9 (49.8)
2	82.0 (32.9)	68.0 (28.0)		150.1 (30.3)	151.3 (31.0)
A	43.0 (17.3)	43.0 (17.7)		85.8 (17.3)	84.8 (17.4)
IS	3.0 (1.2)	6.0 (2.5)		9.9 (2.0)	9.2 (1.9)
Hb (mean ± SD)*	11.78 ± 1.83	10.18 ± 1.67	0.909	11.72 (1.76)	10.20 (1.68)	0.882
BR (%)*	83.0 (33.3)	72.0 (29.6)	0.080	169.2 (34.1)	143.0 (29.3)	0.105
CR (%)*	6.0 (2.4)	37.0 (15.2)	0.464	18.2 (3.7)	69.1 (14.1)	0.374
Cystectomy (%)*	10.0 (4.0)	48.0 (19.8)	0.501	21.9 (4.4)	93.1 (19.1)	0.467
Nephroureterectomy (%)*	249.0 (100.0)	243.0 (100.0)	< 0.001	495.6 (100.0)	488.2 (100.0)	< 0.001
CSS (%)*	27.0 (10.8)	18.0 (7.4)	0.120	54.0 (10.9)	37.0 (7.6)	0.115
OS (%)*	46.0 (18.5)	51.0 (21.0)	0.063	87.1 (17.6)	108.6 (22.3)	0.118

IPTW, inverse probability of treatment weighting; UTUC, upper urinary tract urothelial carcinoma; ESA, Erythropoiesis-stimulating agents; SD, standard deviation; BMI, body mass index; CCI, Charlson Comorbidity Index; Hgb, hemoglobin; BR, bladder recurrence; CR, contralateral recurrence; CSS, Cancer specific survival; OS, Overall survival.

^*Observations endpoint without IPTW-adjusted.